These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35326759)

  • 1. The Risk of
    Hall RG; Cole TJ; Shaw C; Alvarez CA
    Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
    Jiang Y; Sarpong EM; Sears P; Obi EN
    Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
    Whitney L; Nesnas J; Planche T
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile.
    Patel N; Lowry C; Morgenson D; Shah V; Stornelli N; Lodise TP
    Pharmacotherapy; 2021 Feb; 41(2):212-219. PubMed ID: 33455007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience.
    Alsoubani M; Chow JK; Rodday AM; McDermott LA; Walk ST; Kent DM; Snydman DR
    J Infect Dis; 2024 May; ():. PubMed ID: 38779889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of
    Alsoubani M; Chow JK; Rodday AM; Kent D; Snydman DR
    Open Forum Infect Dis; 2024 Jan; 11(1):ofad622. PubMed ID: 38204563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
    Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
    Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
    Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
    Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
    Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
    Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
    Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
    Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
    Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin.
    Sambol SP; Skinner AM; Serna-Perez F; Owen B; Gerding DN; Johnson S
    Microbiol Spectr; 2023 Mar; 11(2):e0051723. PubMed ID: 36975811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.